ALKSAlkermes plc
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +7% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ALKS is trading
Alkermes plc is +46% over the past year while the S&P 500 is +18%: 28 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +7.3%
vs 200-day average · close to trend
- RSI (14)
- 33
RSI (14) · neutral
- Below its 52-week high
- 23%
Below its 52-week high
Details›
- Last close2026-10-09
- $40.63
- 1 monthS&P 500 +2.7%
- −12%
- 1 yearS&P 500 +18%
- +46%
- 5 yearsS&P 500 +88%
- +33%
- vs 50-day average$46.10
- −12%
- 52-week high
- $52.99
- 52-week low
- $27.13
- Annualised volatility
- 38%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$2.9M
| Year | Return |
|---|---|
| 2026 (year to date) | +45% |
| 2025 | −2.7% |
| 2024 | +3.7% |
| 2023 | +6.2% |
| 2022 | +12% |
| 2021 | +17% |
| 2020 | −2.2% |
| 2019 | −31% |
| 2018 | −46% |
| 2017 | −1.5% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +5.1% |
| Feb | 10 | 5 of 10 | +1.4% |
| Mar | 10 | 6 of 10 | −0.18% |
| Apr | 10 | 3 of 10 | −4.4% |
| May | 10 | 7 of 10 | +3.1% |
| Jun | 10 | 7 of 10 | +4.9% |
| Jul | 11 | 5 of 11 | −0.19% |
| Aug | 11 | 4 of 11 | −1.3% |
| Sep | 11 | 4 of 11 | −2.5% |
| Oct | 11 | 5 of 11 | −2.0% |
| Nov | 10 | 6 of 10 | +2.0% |
| Dec | 10 | 5 of 10 | +0.99% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #17 of 41 by RyuScore